At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 163 enrolled
Drug / intervention
JUVÉDERM VOLBELLA® XC injectable geldevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Single-blind, Randomized, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLBELLA® XC Injectable Gel for Correction of Infraorbital Hollowing
In Brief
A Phase 3 clinical trial evaluating JUVÉDERM VOLBELLA® XC injectable gel for Infraorbital Hollowing. Completed, enrolled 163 participants across 15 sites.
Detailed Summary
The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM® VOLBELLA™ XC in adult participants seeking correction of hollowing of the tear troughs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfraorbital Hollowing
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedFeb 2018
Primary CompletionOct 2018
Study CompletionAug 2019
TodayJul 2026
First PostedFeb 1, 2018
Enrollment StartJan 26, 2018
Primary CompletionOct 17, 2018
Study CompletionAug 22, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.4 years ago
Interventions
JUVÉDERM VOLBELLA® XC injectable geldevice
JUVÉDERM® VOLBELLA™ XC dermal filler injected into the infraorbital and adjacent area.